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The unexpected diversity of the human microbiome and metabolome far exceeds the complexity of the
human genome. Although we now understand microbial taxonomic and genetic repertoires in some popula-
tions, we are just beginning to assemble the necessary computational and experimental tools to understand
the metabolome in comparable detail. However, even with the limited current state of knowledge, individual
connections between microbes and metabolites, between microbes and immune function, and between
metabolites and immune function are being established. Here, we provide our perspective on these connec-
tions and outline a systematic research program that could turn these individual links into a broader network
that allows us to understand how these components interact. This program will enable us to exploit connec-
tions among the microbiome, metabolome, and host immune system to maintain health and perhaps help us
understand how to reverse the processes that lead to a wide range of immune and other diseases.Introduction
The human microbiota (the collection of microbes that inhabit
our bodies) and human microbiome (the collection of DNA
from microbes) are remarkably, and unexpectedly, diverse.
Although the Human Microbiome Project (HMP) (Peterson
et al., 2009; Turnbaugh et al., 2007) was predicated on the
assumption that we would share a large core of microbial line-
ages, sprinkled with a diversity of ‘‘peripheral’’ lineages that
make each of us unique (Turnbaugh et al., 2007), this hypothesis
was not validated by empirical evidence after the completion
of the HMP. Indeed, the first deep sequencing of multiple fecal
samples from each of three individuals revealed that the differ-
ences between individuals are large. The differences between
individuals are substantially greater than the differences within
an individual at different sampling sites along the distal large in-
testine (Eckburg et al., 2005). This pattern of diversity has subse-
quently been reinforced in different body habitats (Costello et al.,
2009; Findley et al., 2013; Grice et al., 2009; Human Microbiome
Project Consortium, 2012) and with larger subject populations,
especially in the gut (Qin et al., 2010; Turnbaugh et al., 2009;
Yatsunenko et al., 2012). Even within healthy Western adults,
studies routinely show that different people can be >90%
different in terms of the populations of microbes in their gut; in
other words, a microbial cell chosen from person A and a micro-
bial cell from person B will be different at the species level more
than 90% of the time. Additionally, the dynamic range of the
most common microbes is hugely variable. Within the microbes
identified by the European MetaHIT Project as ‘‘core,’’ meaning
that they were found in at least 90% of the healthy European
cohort studied, the dynamic range was several orders of magni-
tude different for each species—in other words, any microbial824 Immunity 40, June 19, 2014 ª2014 Elsevier Inc.species found with at least 10% abundance in one person was
at least as rare as one cell in 1,000 in another person in the cohort
(Qin et al., 2010).We are at the leading edge of understanding the
implications of this tremendous diversity at the metabolic level
and of the interplay among the gut microbiota, metabolic func-
tion, and the immune system. To address the molecular connec-
tions between gut bacteria and immune function, there now
exists a collection of synergistic technologies that will allow rapid
progress in untangling these complex interactions in ways that
can be harnessed to promote health.
Grappling with a Diverse Microbiota
Although the microbiota is incredibly diverse, and much of
this diversity still consists of uncharacterized species and genes,
defining this diversity for some populations appears within
reach given the multitudes of microbiome profiling projects to
date. Recent large-scale studies, such as the HMP and MetaHIT
efforts, are beginning to saturate the gene catalog for healthy
Western cohorts (Human Microbiome Project Consortium,
2012; Qin et al., 2010). This diversity is usually assessed by a
technique called rarefaction: as additional subjects are exam-
ined, a curve is plotted with the number of subjects on the x
axis and the number of unique taxa or genes on the y axis. As dis-
covery of this microbial ‘‘parts list’’ becomes more complete,
finding a new unique part requires additional people and subsets
of populations, so the curve levels off until, at last, it reaches
an asymptote when all the parts have been discovered. Similar
saturation of rarefaction curves is now being observed for
several clinical conditions in which the microbiome is involved,
such as obesity (Le Chatelier et al., 2013) and diabetes (Qin
et al., 2012). This finding has several important implications: first,
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available technologies; second, that a reference database can
be constructed, allowing interpretations of new sequences on
the basis of matching findings to what is known already rather
than computationally driven de novo assembly and annotation
procedures; and third, that markers can be discovered within
this known universe and then prioritized for further laboratory
characterization and experimental work, including studies in an-
imal models, such as those using gnotobiotic mice. However, a
cautionary note appears needed: studies of children and of non-
Western individuals reveal completely different configurations of
the microbiome and the microbiota (Yatsunenko et al., 2012).
Consequently, substantial additional workwill be required for ex-
tending these techniques to cover the diverse complexity found
in humanity, a notion that can be extended to various conditions
in relevant animal models.
Another previously made key assumption that was not vali-
dated by subsequent studies is that diversity in the microbiota
correlates directly to diversity in themicrobiome in terms of over-
all metabolic functions. This property, that different assemblages
of species converge on very similar functional profiles, was first
observed in the human gut (Turnbaugh et al., 2009) and then
more recently extended to other human body sites (Human Mi-
crobiome Project Consortium, 2012). Conceptually, this makes
sense in retrospect and by analogy to larger-scale ecosystems:
two grasslands might look relatively similar to each other, espe-
cially in comparison to two forests, even in situations where
essentially none of the species in either grassland is shared
(Hamady and Knight, 2009). Although particular species and
functions seem to be highly individualized (Fierer et al., 2010;
Schloissnig et al., 2013) and even stable over time (Caporaso
et al., 2011; Faith et al., 2013) and although associations be-
tween genetic lineages of microbes and functional capacities
are so highly conserved that functional profiles can be predicted
accurately from species distributions (Langille et al., 2013), the
overall functional profiles appear remarkably static in healthy
subjects overall. Although a few studies have correlated the
microbiota to the microbiome (Muegge et al., 2011) and to the
metabolome (Ridaura et al., 2013; Smith et al., 2013a), the rela-
tionships among the various ‘‘omics’’ levels and with the host
immune system remain largely unexplored.
Metabolite Diversity Might Exceed Even Microbial
Diversity
In contrast to the microbiota and the microbiome, which we are
now starting to saturate for some populations, the metabolome
is extremely diverse and remains largely undescribed and unde-
fined. For example, tissue-culture cells grown in pure culture
remain poorly characterized in terms of their metabolic profiles,
underscoring the dearth of knowledge about more complex bio-
logical systems. The human genome contains approximately
20,000 protein-coding genes, but our metabolomic profile is
muchmore complex—it numbers at least 500,000, and individual
classes of compounds, such as lipids and oligosaccharides,
potentially harbor very high levels of diversity simply on combina-
torial grounds (Quehenberger et al., 2010; Shevchenko and
Simons, 2010). For example, the molecular family of six common
triacylglycerides that use at least 20 different fatty acids provides
the combinatorial capacity to make more than 40,000 differentlipids (and in reality, there are many more fatty acids, leading to
further combinatorial explosion). This calculation does not take
in account the many modifications that fatty acids undergo or
the many modifications triacylglycerides undergo themselves.
This is just one description of one subfamily of one molecular
family. Furthermore,many specializedmetabolites, including sec-
ondarymetabolites, naturalproducts, quorumsensors, andsmall-
molecule virulence factors, are produced by nearly all microbes.
Some organisms have the metabolic capacity to make as many
as 50 of these. Thesemolecules are optimized to regulate the sur-
rounding environment and to control and alter biology at the host-
microbe interface by driving microbial community composition
and host immune regulation (Figure 1). In turn, these molecules
drive complex physiological feedback loops (Nicholson et al.,
2005). Thesemicrobialmolecules havebeen exploited in the clinic
as cholesterol-lowering drugs, immune regulators, or antibiotics.
On the basis of the genome sequences now available, there are
strong indications that thousandsmore of thesemicrobial effector
molecules remain to be discovered in the human microbiota.
Finally, given that the diversity of diet-derived cells and microbial
cells present in the gut dwarf human cell diversity, as well as
outnumber them, it seems appropriate to assume that the vast
majority of metabolites in our bodies are not of human origin and
that microbes significantly alter the humanmicrobiome (Figure 1).
The number of potential gut bacterial metabolites is thus
currently unknown and includes molecules of dietary, host, and
microbial origin. Furthermore, there is complex crosstalk among
hosts, microbes, and the transformations that the metabolites
undergo. These complex transformations often define the
ultimate function of the molecules that are present (Martin
et al., 2007). The tools currently available for harvesting and visu-
alizing the diversity of microbial metabolites, including both pri-
mary and specialized metabolites, do not presently capture this
complexity. Consequently, the state of knowledge for metabo-
lites resembles the situation for microbes a decade ago: we
know that there are myriad metabolites of potential microbial
origin or of microbial transformation, and we know that some
are shared among people and some are unique. In a handful of
examples that are clinically interesting, metabolites and their as-
sociation with clinical phenotypes have been described via tar-
geted techniques (Martin et al., 2007). For example, people are
similar in some of the common metabolites they contain (such
as amino acids or short-chain fatty acids in the gut), and some
of this variation correlates with disease. However, we lack a clear
understanding of howmany (andwhich)microbialmetabolites in-
fluence host biology, as well as the overall nature of variation in
the general population. This is due to the current limitations in
technical approaches capable of building a comprehensive me-
tabolomic ‘‘parts list’’ on a population-level scale. If we perform
the analysis at the level of pathways rather than individualmetab-
olites, they might appear to be more similar among individuals,
but this apparent similarity might arise from limitations in the bio-
informatics tools used. Just as we are starting to appreciate that
our microbiomes augment our genome’s capabilities and indeed
can be more predictive than our human genome for classifying
people as healthy or diseased (Knights et al., 2011; Le Chatelier
et al., 2013), we need to expand the concept of our metabolome
to include the microbially produced and microbially modulated
metabolites as factors contributing to pathogenesis.Immunity 40, June 19, 2014 ª2014 Elsevier Inc. 825
Figure 1. The Microbe-Host Interface
Individual differences, including sex-specific differences between men and women (blue and red, respectively), might control the microbiota or interact with the
microbiota to influence immune function in several ways, including the release of metabolites and direct microbial interactions. Much of this interface occurs in
the gut (shown in the inset in the female figure), where the intestinal wall provides an interface between metabolites and immunological processes in the gut and
the influence of thesemetabolites and immunological processes on the host systemically. In addition to having normal metabolic function, specializedmicrobially
produced metabolic products (second inset), such as signaling molecules and antibiotics, might play a key and specific role in driving microbial community
composition and subsequently the microbiome.
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New Frontier
Immunological responses by the host are also diverse, although
our view of this diversity has been limited by the application of
targeted approaches. Traditional research in immunology has
focused on diverse immune responses to pathogenic infection.
Viewed through this perspective, conventional wisdom in the
field has guided studies to determine how the immune system
attempts to control infectious agents, how pathogens subvert
the arsenal of innate and adaptive immune mechanisms, and
how individual mutations in the host might affect these pro-
cesses. We now appreciate that host-microbial interactions at
various body surfaces cannot be fully captured in this simple
framework but will most likely need to involve complex and dy-
namic processes. These processes include not only immunity
to pathogens but also immune ignorance and/or tolerance
mechanisms for symbiotic bacteria and opportunistic pathogens
that are routinely found in microbiome studies. The functions of
the immune system might even include promoting the growth
of beneficial microbes, as well as limiting the growth of harmful
microbes, given that the same microbe could be harmful or
beneficial in the context of different body sites, host physiolog-
ical status, and so forth. Conceivably, individual members of
the gut microbiota can have diverse effects on the immune
system such that some indigenous organisms promote proin-
flammatory responses while others promote anti-inflammatory
reactions. A handful of microbes have been experimentally
shown to directly affect infection (by other species, including
bacteria, eukaryotes, and viruses), autoimmunity, and inflam-
mation in animal models. These examples together with the
genomic information indicate that a vast constellation of mi-
crobes with bioactive properties is waiting to be discovered.
Consequently, the interplay between the gut microbiota and
the immune response is likely to be far more diverse and dy-
namic thanwe currently appreciate, and the role thatmetabolites826 Immunity 40, June 19, 2014 ª2014 Elsevier Inc.play in the evolutionary connection between symbiotic microbes
and their hosts is a frontier of research in the field.
To date, observations connecting the microbiome, the metab-
olome, and immunological responses have been sporadic and
incomplete. Investigators have made observations, like flash-
bulbs going off in the dark, but a systematic approach has not
yet been applied in any complex biological system. Therefore,
although we know that connections exist (as detailed below),
only a small fraction of these connections are known at present.
In part, this lack of a unified approach is due to ‘‘language bar-
riers’’ among the practitioners of the different disciplines and
the lack of a unified research community making a concerted
effort to bring their collective expertise to bear on these prob-
lems. Going forward, better ways of representing and visualizing
the data—especially methods that translate across the various
highly multivariate data sets collected by each discipline, as
well as research practices and communities that allow transla-
tion of results among disciplines—will be critical for uncovering
the diverse molecular interplay between gut microbial metabo-
lites and the immune system. This perspective describes the
current state of the art in our understanding of microbial-metab-
olite-immune connections and provides a framework for the vast
and exciting potential of developing an integrated program to
decode the molecular conversation between mammals and their
microbiomes. In doing so, we describe a microbial-metabo-
lite-based roadmap for explaining current observations and
discovering new interactions in ways that will be useful for basic
research, predictive modeling, patient stratification, and poten-
tially the development of transformative treatments for various
diseases.
Microbial Metabolism and Inflammation
The microbiome produces a wide range of metabolites and has
a pervasive effect on various host processes, although many
of these effects are just starting to be explored in detail. It has
Figure 2. A Simplified Depiction of the Effects of Specific Gut
Microbial or Microbial-Mammalian Cometabolites on Different
Organ Systems, Including the Immune System
Short-chain fatty acids (SCFAs) and polysaccharide A (PSA) affect Treg cell
development. Peptidoglycan (PGN) affects bone resorption. Trimethylamine
N-oxide (TMAO) affects the vascular system and influences the risk of heart
disease. 4-ethylphenol sulfate (4EPS) affects brain function and leads to
anxiety-like behavioral defects similar to those observed in autism. Although
some of these examples illustrate harmful effects, it is likely that many
microbially produced metabolites in addition to SCFAs and PSA produce
beneficial effects on the host, although these tend to be less well studied.
Additional abbreviations are as follows: 4EP, 4-ethylphenol; and TMA,
trimethylamine.
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olizing otherwise indigestible food components, such as dietary
fiber, but additional functions are being discovered at a rapid
pace. For example, microbial production of vitamins and amino
acids is important during human infant development (Yatsu-
nenko et al., 2012) and has been implicated inmalnutrition (Smith
et al., 2013a), which in turn affects susceptibility to a variety of in-
fectious diseases. Similarly, different bacteria in different people
have variable effects on the metabolism of drugs, ranging from
the painkiller acetaminophen (Clayton et al., 2009) to the cardiac
glycoside digoxin (Haiser et al., 2013) to the cancer drug cyclo-
phosphamide (Viaud et al., 2013), and most likely also have an
effect on immunomodulatory drugs.
Microbial metabolites have long been implicated in metabolic
functions both inside and outside the gut (Figure 2). Of these,
short-chain fatty acids (SCFAs), breakdown products of dietary
fiber (such as butyrate), are especially important as an en-
ergy source for intestinal epithelial cells. Recent studies have
expanded the role of SCFAs from gut bacteria to reveal impacts
on the immune system (for more detail, see the accompanying
review by Thorburn et al., 2014 in this issue of Immunity). In brief,
in ulcerative colitis, an inflammatory bowel disease (IBD), SCFAsare reduced, and treatment with dietary fiber provides clinical
benefits. Germ-free mice without any gut bacteria have lower
SCFA levels than do animals with a complex microbiota (Mas-
lowski et al., 2009). This phenotype is attributed to increased
intestinal inflammation in a mouse model of IBD, suggesting
that SCFAs provide beneficial or immunosuppressive functions.
Accordingly, deletion of GPR43, a sensor of SCFAs, leads to
exacerbated intestinal disease in mice (Figure 2).
SCFAs directly affect the development and function of anti-
inflammatory regulatory T (Treg) cells, which restrain uncontrolled
inflammation. SCFAs, and in particular propionate, increase both
the proportion and the absolute count of Treg cells in germ-free
mice and augment Treg cell function to promote suppression in
colitis models (Smith et al., 2013b). Bacteria such as spore-form-
inggroupXIVaClostridiaappear toproducebutyrate that alsopro-
motes Treg cell differentiation both in vivo and in vitro (Furusawa
et al., 2013). The effects of SCFAs extend beyond Treg cells
and the gut. For example, mice fed a high-fiber diet have both
increased SCFA levels and protection from allergic inflammation
in the lungs, attributed to effects on hematopoiesis of innate im-
mune cells by propionate (Trompette et al., 2014). Collectively,
these studies highlight how gutmicrobial metabolites, specifically
SCFAs, provide benefits to the host via enhancing the innate and
adaptive immune systems in various animalmodels and contexts.
Future work will be needed for determining whether this mecha-
nism translates to humans. Dietary and microbial interventions
for allergic, inflammatory, and autoimmune diseases would be
relatively safe and feasible approaches that could be rapidly vali-
dated in many populations and societies around the world.
Specific Immune Signals from Microbially Produced
Metabolites
Many of the diseases that have been linked to the microbiome
also have an immunological component. These conditions
include IBD (Frank et al., 2011; Frank et al., 2007; Gevers et al.,
2014), obesity (Cotillard et al., 2013; Le Chatelier et al., 2013;
Leyet al., 2006;Ridaura et al., 2013;Turnbaughet al., 2009), rheu-
matoid arthritis (Scher et al., 2013), food allergies (Ling et al.,
2014), asthma (Fuchs and von Mutius, 2013), and animal models
of multiple sclerosis (Berer et al., 2011; Lee et al., 2011), autism
(Hsiao et al., 2013), resistance to infection (Abt et al., 2012; Ichi-
nohe et al., 2011; Khosravi et al., 2014), and awide range of other
conditions. Examples of specific microbial triggers, including
lipopolysaccharide (LPS), double-stranded RNA (dsRNA), and
quorum-sensing molecules (homoserine lactones and their
derivatives), are also well known. We will summarize some of
this literature, but these topics have been extensively reviewed
elsewhere. Microbe-brain connections are also increasingly
emerging as interesting and important (Cryan and Dinan, 2012).
For example, neurotransmitters, such as dopamine and seroto-
nin, are either produced by bacteria or stimulated in host cells
by the presence of bacteria; viewing these neurotransmitters as
metabolites that affect the immune system is an important
emerging perspective (Baganz and Blakely, 2013).
Metabolites and Pattern Recognition by the Immune
System
Of particular interest is how molecules produced by bacteria,
including metabolites, can act in pattern recognition by theImmunity 40, June 19, 2014 ª2014 Elsevier Inc. 827
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pattern-recognition receptors (PRRs) that recognize conserved
microbial ligands. Binding to these ligands alerts the host to
the presence of the microbes that produce them. This class of
molecules, commonly termed pathogen-associated microbial
patterns (PAMPs), has primarily been studied in the context of
pathogenesis. Remarkably, some PAMPs produced by the gut
microbiota can also positively affect the immune system and
health. For example, in a model of intestinal injury and inflam-
mation, more severe disease has been shown to occur in the
absence of commensal microbes, but this effect can be amelio-
rated by the addition of LPS or lipotiechioc acid, two highly
conserved products produced by microbes (Rakoff-Nahoum
et al., 2004). The beneficial effects of microbial molecules extend
beyond the gut. For example, peptidoglycan (a PAMP) from gut
bacteria augments the function of innate immune cells that orig-
inate from bone marrow, such as neutrophils, to help fight off
systemic bacterial infection (Clarke et al., 2010). Depletion of
gut bacteria also renders mice susceptible to influenza virus
infection in the lungs and to systemic lymphocytic choriomenin-
gitis virus infection (Abt et al., 2012; Ichinohe et al., 2011). The
administration of PAMPs restores the host’s ability to control
infection, demonstrating that microbial molecules previously
studied in the context of infection can actually have host-protec-
tive functions when produced at physiological amounts by gut
bacteria. Finally, germ-free animals are defective in the differen-
tiation of specific innate immune cell subsets that are critical for
resistance to systemic bacterial infection (Khosravi et al., 2014).
Oral administration of microbial ligands restores these defects,
illustrating that microbial molecules regulate immune system
development at its core—during hematopoiesis.
Another example of a PAMP that can act as a beneficial signal,
and not just as a pathogenic trigger, is polysaccharide A (PSA)
from the human commensal Bacteroides fragilis (Mazmanian
et al., 2005). PSA signals to the immune system through a spe-
cific PRR to induce development and function of Foxp3+ Treg
cells, which prevent inflammation in the gut and CNS through
the effects of interleukin-10 (IL-10) (Ochoa-Repa´raz et al.,
2010; Round and Mazmanian, 2010). Therefore, not all interac-
tions between microbial molecules and PRRs lead to inflamma-
tion and disease (Chu and Mazmanian, 2013). One can therefore
view PRRs as sensors not of pathogens but of microbes in gen-
eral. Thus, PRRs can be considered the immune system’s
‘‘eyes,’’ which observe themicrobial world and can be potentially
beneficial or harmful to the host depending on the context of the
interaction. This perspective suggests a reconsideration of the
term PAMP to a more broad terminology proposed by many
advocating the use of microbial-associated molecular patterns,
or MAMPs (Mackey and McFall, 2006). The situation is some-
what analogous to antibiotics, which are often used in lower
concentrations as signaling molecules in natural microbial eco-
systems (Linares et al., 2006).
Microbially Derived Metabolites Affect the Immune
System
The human immune system is significantly affected by many
common microbially derived molecules. LPS is perhaps the
best-studied microbially produced molecule affecting the in-
flammatory status of humans or mice; as of this publication,828 Immunity 40, June 19, 2014 ª2014 Elsevier Inc.there are over 85,000 articles on this topic in PubMed. However,
other bacterial molecules are also important. Tryptophan (which
is an essential amino acid in humans and which we obtain both
from our diet and from tryptophan biosynthesis by our microbial
symbionts), as well as its microbially produced breakdown prod-
ucts, plays an important role in the immune system. For example,
in mice fed unrestricted tryptophan diets, lactobacilli (typically
thought of as anti-inflammatory, although the genus Lactoba-
cillus contains considerable genetic and phenotypic diversity)
produce indole-3-aldehyde, which upregulates IL-22 in the
host and induces a mucosal response limiting colonization of
the gut by the fungal pathogen Candida albicans (Zelante
et al., 2013). Another interesting case is the common quorum-
sensing molecule N-(3-oxo-dodecanoyl) homoserine lactone,
which disrupts NF-kB signaling (Kravchenko et al., 2008).
Although no homoserine lactones have yet been detected in
the gut, the gut microbiome harbors many genes capable of pro-
ducing this class of signaling molecules (Swearingen et al.,
2013). Part of the challenge in detecting homoserine lactones
is that they are rapidly degraded by microbes (Moroboshi
et al., 2005; Tinh et al., 2007) and that they are only produced
under specific conditions, even by bacteria that contain the rele-
vant genes (Wang et al., 2006). Better methods for detecting
transiently produced and rapidly degraded molecules might be
required in order to pinpoint the role of such molecules in
shaping the gut immune system.
Microbes also contribute to the alteration of arachidonic-
acid-derived lipids. Although mostly studied in the context of
pathogenesis (Eberhard et al., 2002), many organisms that can
metabolize these lipids are found in the normal human micro-
biota and alter the amount of arachidonic acid and its down-
stream metabolites, such as prostaglandins and leukotrienes.
For example, colonizing germ-free mice with Bacteroides
thetaiotaomicron (B. theta) or colonizing them with B. theta and
Bifidobacterium longum together increases prostaglandin E2
production (Rath et al., 2012). If insufficient arachidonic acid is
present in the diet, it can also be obtained from hydrolysis of
membrane lipids, which store arachidonic acid. Arachidonic
acid release can be mediated by several mechanisms. Although
arachidonic acid release has not yet been correlated with or
attributed to the gut microbiota, many microbes, including
manymembers of the normal gutmicrobiota, have the necessary
hydrolases to produce arachidonic acid and most likely perform
roles similar to that of phospholipase A2.
Unknown Functions of Specialized Gene Clusters in the
Microbiome: New Natural Products?
Finally, many specialized metabolite-producing gene clusters
(e.g., natural products, including polyketides, sterols, isopre-
noids, and nonribosomally synthesized peptides) are found
within the gut microbiome. The functions of these metabolites
are almost completely all unknown. Given that many specialized
metabolites isolated from other microbes, such as rapamycin,
are now in clinical use to control immune-mediated diseases, it
is likely that the microbiome has coevolved numerous gene clus-
ters whose products interact with the immune system directly or
indirectly, perhaps in concert with other microbial inhabitants of
the gut. Many microbes produce the classes of molecules we
have described, although understanding the full phylogenetic
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ditions under which they are produced, remains largely unchar-
acterized especially in the context of the community.
Defining a Research Program to Integrate Microbiota,
Metabolism, and Immunity
As noted above, many connections have been made between
microbes and metabolism, between microbes and immunity,
and between metabolites and immunity. However, connections
that link all three are scarce at present. An integrated, compre-
hensive discovery- and hypothesis-driven research program
could yield immense dividends in terms of insights into all three
fields (microbes, metabolism, and immunity) and their fasci-
nating connections. We therefore define approaches that can
systematically identify these connections. In particular, these ap-
proaches will identify small-molecule phenocopies of what are
currently thought to be host immune issues, which might include
known bacterial components. We should aim to design a pipe-
line that transcends descriptive cataloging studies (micro-
biomes, metabolomes, etc.) and instead gets to the underlying
mechanisms that represent the molecular foundations of host-
microbial symbiosis.
A Paradigm for Studies Linking Metabolites, Microbes,
and the Immune System
An example of what this research programmight look like is pro-
vided by a recent study examining the links among the immune
system, the microbiota, and metabolism in a mouse model of
autism (Hsiao et al., 2013). In brief, mice born to mothers subject
to maternal immune activation, which simulates viral infection,
developed symptoms resembling autism spectrum disorders
(ASD), including lack of social interaction, repetitive behavior,
deficits in communication, gut barrier dysfunction, immunolog-
ical changes, and dysbiosis of themicrobiome. This combination
of symptoms has been reported in ASD.
Importantly, the authors observed systematic changes in the
serum metabolome, including overproduction of a metabolite
(4-ethyl phenyl sulfate [4-EPS]) that when individually adminis-
tered to normal mice recapitulates some of the same pheno-
types. Introduction of a probiotic strain of B. fragilis resulted in
lowered 4-EPS production and also ameliorated intestinal and
behavioral abnormalities. This combination of immunological
manipulation, generation of lead microbes and metabolites
through untargeted microbiome and metabolite profiling, and
tests in gnotobiotic mice (initially germ-free mice colonized
with defined communities of microbes) provides a paradigm
for identifying connections, although we emphasize that such
studies that have been performed to date only scratch the sur-
face of the full range of microbial and metabolic components
of the altered response.
Toward an Integrative Pipeline
A pipeline for identifying novel connections in higher throughput
might include a program to screen small-molecule compound
libraries for effects on immune cells in tissue culture to both iden-
tify metabolites produced by bacteria or by bacterial commu-
nities that have been linked to diseases and test candidate
microbes and metabolites, alone or in combination, in gnotobi-
otic mice. Additionally, screening bacteria in high throughput inorganoid systems with reporter gene assays to identify immuno-
modulatory effects might be more facile than using live animals.
Essentially, the pipeline needs to include (1) case-control studies
to establish that there are microbial or metabolic differences to
be explained in the first place, (2) spatial mapping and multiva-
lent characterization (microbiome, metabolome, immune reper-
toire) to inform hypotheses about possible connections, and (3)
prospective longitudinal studies in humans and preclinical
experimental manipulation studies in mice or other model sys-
tems to establish causality. This approach might ultimately
lead to drug candidates for clinical trials in humans.
This pipeline will be complicated by the bidirectional connec-
tions between the microbiome and the immune system. For
example, genetic deletion of TLR5, an innate immune system
component that recognizes bacterial flagellin, results in a sub-
stantially altered bacterial community, which in turn (depending
on the microbial background) can lead to phenotypes ranging
from metabolic syndrome (Vijay-Kumar et al., 2010) to colitis
(Carvalho et al., 2012a; Carvalho et al., 2012b), the latter of which
stems from an inability to regulate proinflammatory proteo-
bacteria. Additional research has shown that, instead of produc-
ing a single altered microbiome, TLR5-deficient mice produce
different microbiota coupled to different phenotypes that can
be transmitted vertically within a family (this is facilitated by the
fact that mice are coprophagous) (Ubeda et al., 2012). Micro-
biome profiling and specific cytokine assays have been per-
formed in these animals, and some of the phenotypes have
been transferred to previously germ-free mice by transmission
of the altered microbiota. Fascinatingly, such phenotypes
include the behavioral phenotype that causes the TLR5-deficient
mice to overeat and thereby develop metabolic syndrome. Un-
fortunately, however, the combination of microbiome, metabo-
lite, and immunological profiling in a longitudinal study design
that would be ideal for identifying leadmicrobes andmetabolites
has not yet been performed.
Moving Beyond the Gut
In our discussions thus far, we have mainly focused on the gut
and on the systemic effects of gut microbes at distal sites
because these have been the best studied to date. However,
there is intriguing but preliminary evidence that there might be
microbes at sites previously thought to be sterile in healthy
adults, including the lungs, adipose tissue, the pancreas,
the liver, amniotic fluid, and even the brain. Studying whether
microbes inhabit these sites in gnotobiotic mice and the immu-
nological and host responses at distal sites, together with the
metabolites produced by the host, the bacteria, or the combina-
tion of the two, has substantial potential for uncovering funda-
mentally new mechanisms of disease. Microbial metabolites
are dramatically understudied in the context of the human ner-
vous system, immune system, and metabolism. We propose
that future studies should focus on interactions between micro-
bial metabolites and the host in various contexts, conditions, and
diseases.
Finally, most studies to date have treated a given body
compartment, such as the skin or the gut, as a homogeneous
assemblage of microbes, yet the spatial and dynamic associa-
tions of particular microbes, their metabolites, and components
of the immune response are also critical for understandingImmunity 40, June 19, 2014 ª2014 Elsevier Inc. 829
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Perspectivefunction at these sites. For example, knowing which bacteria
colonize which crypts in the gut (Lee et al., 2013; Pe´dron
et al., 2012), and how they stimulate stem cell proliferation
and other factors linked to IBD or cancer, might provide impor-
tant information not accessible in readouts of the microbiome
and/or metabolome through stool samples. In the context of
IBD, for example, biomarkers in treatment-naive patients can
be more clearly assessed in mucosal biopsies than in stool
(Gevers et al., 2014), the latter of which is frequently used for mi-
crobiome assessments because of its accessibility via noninva-
sive sampling. Especially given the success of imaging mass
spectrometry in understanding how bacteria interact with one
another to produce metabolites that they would not produce
in isolation in pure culture (Traxler et al., 2013; Yang et al.,
2009), as well as interkingdom interactions between bacteria
and fungi (Moree et al., 2012), the potential for extending these
spatially defined studies into the human body is immense.
Furthermore, understanding how microbes and metabolites
change over time in various contexts might lead to predictive
models for disease diagnosis and patient stratification. The
pipeline we propose should reveal how microbes are located
spatially: correlating specific metabolite features with the micro-
biome distribution and then testing whether the molecules that
colocalize affect the immune system will provide an especially
powerful mechanism for generating lead compounds for the
downstream studies that might extend into the clinic. Unfortu-
nately, this sampling is destructive by current methods; the
discovery of nondestructive readouts of the microbiome and
metabolome would permit longitudinal within-subjects study
designs, which, given high variability among individuals, might
be important for clinical translation of these discoveries to
improve human health.
Conclusion
A number of specific interactions among microbes, metabolites,
and the immune system have now been discovered; although
many of these examples were identified in the context of specific
diseases, the broader network of these connections is most
likely critical for a wide range of normal biological processes in
the host. Development of a pipeline that allows for larger-scale
discovery of these connections in both health and disease in
humans and animal models is most likely within our reach via
technologies that exist today or are in current development. In
particular, in the same way that microbe and gene catalogs are
now saturating in many populations, saturating the metabolite
repertoire and building reference databases that allow matching
to known standards will accelerate metabolomic discoveries
considerably. Similarly, ‘‘multiomics’’ approaches in which the
microbiome, the metabolome, and the immune repertoire are
assessed simultaneously in the same biological specimens will
provide considerable advances over current approaches. The
prospect of a fundamental advance in our understanding of
biology, not only of the parts list but also of the interactions
that lead to a healthy supraorganism, and an engineering-level
basis for developing technologies to arrest or reverse processes
that lead to disease is exciting and feasible. Overcoming the bar-
riers in communication and philosophies among diverse disci-
plines and among different experimental and computational
technologies might catalyze a revolution in understanding the830 Immunity 40, June 19, 2014 ª2014 Elsevier Inc.microbe-metabolite-immune connection in numerous ways
that will benefit mankind.
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